English
简体中文
Total: £ 56.28
Published Date: 2026-04-08 | Pages: 117 | Tables: 119 | Pharma & Healthcare
The global Alpha 1 Antitrypsin Deficiency Treatment market was valued at US$ 2387 million in 2025 and is anticipated to reach US$ 4327 million by 2032, at a CAGR of 9.0% from 2026 to 2032.
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.
This report delivers a comprehensive overview of the global Alpha 1 Antitrypsin Deficiency Treatment market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Alpha 1 Antitrypsin Deficiency Treatment. The Alpha 1 Antitrypsin Deficiency Treatment market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Alpha 1 Antitrypsin Deficiency Treatment market comprehensively. Regional market sizes by Indication, by End Users, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Alpha 1 Antitrypsin Deficiency Treatment manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Indication, by End Users, and by region.
Market Segmentation
By Company
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences
Segment by Indication
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other
Segment by End Users
COPD
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Indication, by End Users, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Alpha 1 Antitrypsin Deficiency Treatment companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Indication, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by End Users, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Indication
1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication: 2021 vs 2025 vs 2032
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Diabetes
1.2.6 Other
1.3 Market by End Users
1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Growth by End Users: 2021 vs 2025 vs 2032
1.3.2 COPD
1.3.3 Cystic Fibrosis(CF)
1.3.4 Non-CF Bronchiectasis(NCFB)
1.3.5 Diabetes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2021–2032)
2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
2.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2021–2026)
2.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2027–2032)
2.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
2.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
2.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
2.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
2.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue
3.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2021–2026)
3.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2021–2026)
3.2 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Alpha 1 Antitrypsin Deficiency Treatment Revenue
3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio
3.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2025
3.5 Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment Head Offices and Areas Served
3.6 Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment, Products and Applications
3.7 Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by Indication
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2021–2026)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2027–2032)
5 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End Users
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2021–2026)
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2027–2032)
6 North America
6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021–2032)
6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021–2026)
6.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021–2032)
7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021–2026)
7.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021–2032)
8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2021–2026)
8.4 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021–2032)
9.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021–2026)
9.4 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021–2032)
10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021–2026)
10.4 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Details
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.2.5 GlaxoSmithKline Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.3.5 AstraZeneca Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Details
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Details
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.5.5 Teva Pharmaceutical Industries Recent Development
11.6 Takeda
11.6.1 Takeda Company Details
11.6.2 Takeda Business Overview
11.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.6.5 Takeda Recent Development
11.7 Baxter
11.7.1 Baxter Company Details
11.7.2 Baxter Business Overview
11.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.7.5 Baxter Recent Development
11.8 Grifols
11.8.1 Grifols Company Details
11.8.2 Grifols Business Overview
11.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.8.5 Grifols Recent Development
11.9 CSL Behring
11.9.1 CSL Behring Company Details
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.9.5 CSL Behring Recent Development
11.10 Kamada Ltd
11.10.1 Kamada Ltd Company Details
11.10.2 Kamada Ltd Business Overview
11.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.10.5 Kamada Ltd Recent Development
11.11 Chiesi Pharmaceuticals
11.11.1 Chiesi Pharmaceuticals Company Details
11.11.2 Chiesi Pharmaceuticals Business Overview
11.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.11.5 Chiesi Pharmaceuticals Recent Development
11.12 Kedrion Group
11.12.1 Kedrion Group Company Details
11.12.2 Kedrion Group Business Overview
11.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.12.5 Kedrion Group Recent Development
11.13 Vertex Pharmaceuticals
11.13.1 Vertex Pharmaceuticals Company Details
11.13.2 Vertex Pharmaceuticals Business Overview
11.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.13.5 Vertex Pharmaceuticals Recent Development
11.14 ProMetic Life Sciences
11.14.1 ProMetic Life Sciences Company Details
11.14.2 ProMetic Life Sciences Business Overview
11.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
11.14.5 ProMetic Life Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Augmentation Therapy
Table 3. Key Players of Cystic Fibrosis(CF)
Table 4. Key Players of Non-CF Bronchiectasis(NCFB)
Table 5. Key Players of Diabetes
Table 6. Key Players of Other
Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth by End Users (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million), 2021–2026
Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2021–2026)
Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (US$ Million), 2027–2032
Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2027–2032)
Table 13. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
Table 14. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
Table 15. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
Table 16. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (US$ Million), 2021–2026
Table 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players (2021–2026)
Table 19. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Tier (Tier 1, Tier 2, and Tier 3), based on Alpha 1 Antitrypsin Deficiency Treatment Revenue, 2025
Table 20. Ranking of Global Top Alpha 1 Antitrypsin Deficiency Treatment Companies by Revenue (US$ Million) in 2025
Table 21. Global 5 Largest Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue (CR5 and HHI), 2021–2026
Table 22. Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment, Headquarters and Area Served
Table 23. Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment, Products and Applications
Table 24. Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment, Date of General Availability (GA)
Table 25. Mergers and Acquisitions, Expansion Plans
Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (US$ Million), 2021–2026
Table 27. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2021–2026)
Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (US$ Million), 2027–2032
Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2027–2032)
Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (US$ Million), 2021–2026
Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2021–2026)
Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (US$ Million), 2027–2032
Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2027–2032)
Table 34. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (US$ Million), 2021–2026
Table 36. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (US$ Million), 2027–2032
Table 37. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 38. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (US$ Million), 2021–2026
Table 39. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (US$ Million), 2027–2032
Table 40. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 41. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million), 2021–2026
Table 42. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million), 2027–2032
Table 43. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (US$ Million), 2021–2026
Table 45. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (US$ Million), 2027–2032
Table 46. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 47. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (US$ Million), 2021–2026
Table 48. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (US$ Million), 2027–2032
Table 49. Pfizer Company Details
Table 50. Pfizer Business Overview
Table 51. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product
Table 52. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 53. Pfizer Recent Development
Table 54. GlaxoSmithKline Company Details
Table 55. GlaxoSmithKline Business Overview
Table 56. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product
Table 57. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 58. GlaxoSmithKline Recent Development
Table 59. AstraZeneca Company Details
Table 60. AstraZeneca Business Overview
Table 61. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product
Table 62. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 63. AstraZeneca Recent Development
Table 64. Boehringer Ingelheim Company Details
Table 65. Boehringer Ingelheim Business Overview
Table 66. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product
Table 67. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 68. Boehringer Ingelheim Recent Development
Table 69. Teva Pharmaceutical Industries Company Details
Table 70. Teva Pharmaceutical Industries Business Overview
Table 71. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product
Table 72. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 73. Teva Pharmaceutical Industries Recent Development
Table 74. Takeda Company Details
Table 75. Takeda Business Overview
Table 76. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product
Table 77. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 78. Takeda Recent Development
Table 79. Baxter Company Details
Table 80. Baxter Business Overview
Table 81. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product
Table 82. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 83. Baxter Recent Development
Table 84. Grifols Company Details
Table 85. Grifols Business Overview
Table 86. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product
Table 87. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 88. Grifols Recent Development
Table 89. CSL Behring Company Details
Table 90. CSL Behring Business Overview
Table 91. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product
Table 92. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 93. CSL Behring Recent Development
Table 94. Kamada Ltd Company Details
Table 95. Kamada Ltd Business Overview
Table 96. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product
Table 97. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 98. Kamada Ltd Recent Development
Table 99. Chiesi Pharmaceuticals Company Details
Table 100. Chiesi Pharmaceuticals Business Overview
Table 101. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product
Table 102. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 103. Chiesi Pharmaceuticals Recent Development
Table 104. Kedrion Group Company Details
Table 105. Kedrion Group Business Overview
Table 106. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product
Table 107. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 108. Kedrion Group Recent Development
Table 109. Vertex Pharmaceuticals Company Details
Table 110. Vertex Pharmaceuticals Business Overview
Table 111. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product
Table 112. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 113. Vertex Pharmaceuticals Recent Development
Table 114. ProMetic Life Sciences Company Details
Table 115. ProMetic Life Sciences Business Overview
Table 116. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product
Table 117. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (US$ Million), 2021–2026
Table 118. ProMetic Life Sciences Recent Development
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
Table 122. Authors List of This Report
List of Figures
Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Picture
Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Comparison by Indication (US$ Million), 2021–2032
Figure 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication: 2025 vs 2032
Figure 4. Augmentation Therapy Features
Figure 5. Cystic Fibrosis(CF) Features
Figure 6. Non-CF Bronchiectasis(NCFB) Features
Figure 7. Diabetes Features
Figure 8. Other Features
Figure 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (US$ Million), 2021–2032
Figure 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users: 2025 vs 2032
Figure 11. COPD Case Studies
Figure 12. Cystic Fibrosis(CF) Case Studies
Figure 13. Non-CF Bronchiectasis(NCFB) Case Studies
Figure 14. Diabetes Case Studies
Figure 15. Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered
Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2025 vs 2032
Figure 19. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2025
Figure 20. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. The Top 10 and 5 Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2025
Figure 22. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021–2032)
Figure 24. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021–2032)
Figure 28. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. France Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Ireland Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2021–2032)
Figure 36. China Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. India Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Australia & New Zealand Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021–2032)
Figure 44. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021–2032)
Figure 48. Israel Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 52. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 53. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 54. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 55. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 56. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 57. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 58. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 59. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 60. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 61. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 62. Kedrion Group Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 63. Vertex Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 64. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2021–2026)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
